Sunday, May 22, 2011
Thursday, May 19, 2011
New MS Treatments
A number of new multiple-sclerosis medications are beginning to hit the market that promise to make it easier for patients to control flare-ups of the disease and slow its progression.
The drugs, designed to be taken orally, represent a new generation of treatment for MS. Currently, people with the disease can choose from a range of drugs that are administered by injection.
Physicians say many people are reluctant to stick themselves with a needle and would be more comfortable taking a pill once or twice a day. This could encourage a greater number of MS patients to take medication as needed and could spur earlier treatment, which is important since disability from MS is cumulative.
Cost of the new drugs is expected to be high. Novartis AG's Gilenya, so far the only oral MS drug on the market, is priced at about $48,000 a year; the drugs still being developed are expected to cost about the same. That's higher than injectable drugs currently in use, which cost roughly $40,000 a year. Health insurers often pick up most of the expense of MS drugs.
There is a "tremendous desire" among MS patients to begin using oral treatments because of their ease of use, says Joseph Herbert, director of the MS Care Center at NYU Langone Medical Center. Still, he says, many physicians are being cautious about prescribing the oral drugs because their side effects can't be fully assessed until they are used widely for an extended period of time.
Among its side effects, Gilenya can increase a person's risk of infection and potentially lead to toxicity of the liver and an eye disease called macular edema, clinical trials have shown. Some of the oral drugs still in development are expected to have somewhat milder side effects.
The current injectable drugs have generally less severe side effects, including injection-site irritation and flu-like symptoms, although some patients incur more serious problems such as liver damage.
Elizabeth Fuchs, an MS patient on Staten Island, N.Y., began taking Gilenya about two months ago. The 49-year-old was diagnosed with MS about 12 years ago and had tried several injectable medications. Avonex, made by Biogen Idec Inc., required weekly intramuscular injections. She later switched to Copaxone, from Teva Pharmaceutical Industries, which is administered with a daily subcutaneous injection.
"It is just much easier to put a pill in your mouth and take a glass of water," Ms. Fuchs says. Not having to inject herself has made her feel more positive about having MS and even allows her to forget she has the disease, she says.
There is no cure for MS, a chronic, inflammatory condition that occurs when the body's immune system attacks its own central nervous system.
MS, which affects about 400,000 people in the U.S., is marked by symptoms such as vision problems, limb numbness and paralysis. Women are more likely to get the disease than men, and genetic factors may make certain individuals more susceptible, according to the National Multiple Sclerosis Society.
Gilenya, which received Food and Drug Administration approval last fall, is thought to work by reducing the quantity of circulating immune cells that can cause damage in an MS attack. More than 6,500 patients are taking the drug, according to the most recent Novartis data.
Recent data from large clinical trials of other drugs being developed, including Biogen Idec's BG-12, Teva Pharmaceutical's laquinimod, and teriflunomide, from Sanofi-Aventis SA, show they are also effective at controlling MS flare-ups and slowing the progression of disability from the disease. More data on the drugs are expected later this year and, assuming FDA approval, they could all be on the market in late 2012.
The success of any of these drugs isn't guaranteed. Another oral MS drug, Merck KGaA's cladribine, was rejected by U.S. and European regulators earlier this year amid long-term safety-related questions, including an increased cancer rate in patients taking the drug. The company says it remains committed to gaining approval.
Another drug, Biogen's Tysabri, was approved in 2004 but was later temporarily pulled from the market after it was linked to a rare brain infection. Tysabri, administered by intravenous infusion, became available again in 2006 but is limited mainly to patients who don't respond to other treatments.
A recent analysis by Novartis showed that Gilenya reduced relapses among MS patients by 54%. Disability progression was reduced by 30%, using a standard measurement of this process.
Biogen's BG-12 drug reduced MS flare-ups by a similar amount as Gilenya, but with fewer side effects. Smaller reductions in flare-ups were seen in trials with patients using laquinimod (23%) and teriflunomide (31%).
By comparison, Avonex, one of the leading injectable drugs, has been shown to reduce MS flare-ups by 32% and disability progression by 37% over two years.
Physicians say MS cases vary greatly and some drugs won't work for certain patients. Also, it is difficult to directly compare two different clinical trials.
NYU's Dr. Herbert says it is a challenge to get patients to use prescribed injectable therapies. Oral medications' ease of use should increase the number of patients who use the drug as required, he says. This also is expected to encourage some patients, especially those in the initial stages of MS, to begin therapy before the disease advances significantly.
"The data certainly suggest that starting therapy earlier does slow down the progression of the disease," says Timothy Coetzee, chief research officer for the National Multiple Sclerosis Society.
Doctors say they aren't likely to recommend a patient switch to one of the new oral drugs if an injectable drug currently in use is working. Although the ease of taking a pill, rather than an injection, is important, effectiveness of a given drug takes precedence. Patients who switch treatments run the risk of the new drug not being the right fit for them, says Mayo Clinic neurologist Mark Keegan.
Write to Thomas Gryta at thomas.gryta@dowjones.com
Sunday, May 15, 2011
Book Trailer
I just completed a Savvy Authors' Workshop. View my new book trailer on YouTube: http://www.youtube.com/watch?v=ggw6dnVgYro
Labels:
"Book trailers",
"Mary Jo Nickum",
"Mom's Story",
Facebook,
YouTube
Wednesday, April 27, 2011
Blocking Crucial Molecule Could Help Treat Multiple Sclerosis
Neuroscientists have reported identifying a driving force behind autoimmune diseases such as MS, and suggest that blocking this cell-signaling molecule is the first step in developing new treatments to eradicate these diseases.
Researchers led by Abdolmohamad Rostami, M.D., Ph.D., Professor and Chairman of the Department of Neurology at Jefferson Medical College of Thomas Jefferson University, found that GM-CSF, which stands for Granulocyte-macrophage colony-stimulating factor, appears to be the key culprit in the onset of MS. Without GM-CSF, T helper 17 cells (Th17) cells did not induce the MS-like disease in an experimental animal model.
These findings were recently published in an advanced, online publication of Nature Immunology.
Th17 cells have been shown to play an important pathogenic role in humans and experimental models of autoimmune diseases, but the mechanisms behind this have not been understood until now.
There was no connection between GM-CSF and Th17 cells before," said Dr. Rostami. "What we have shown in this paper is that GM-CSF derived from Th17 cells is important in the cell-signaling process that leads to inflammation in the central nervous system."
"Now we know how the Th17 cells work and a better understanding of this mechanism and biology leads to new therapeutics," he adds.
The results suggest that blocking GM-CSF activity may be a successful therapeutic strategy in MS, one of the most common neurological diseases affecting young adults, and other autoimmune diseases, said Dr. Rostami, who is also the Chair of Neurology at Thomas Jefferson University Hospital.
These findings identify the interleukin-23 (IL-23)/ Th17/GM-CSF axis as the major pathway in pathogenesis of autoimmune central nervous system inflammation and likely other autoimmune diseases. IL-23, a known cytokine that causes autoimmune inflammation of the brain, induces production of more GM-CSF in Th17 cells, the researchers explain.
Dr. Rostami, who is also director of the Neuroimmunology Laboratory in the Department of Neurology at JMC, and his colleagues used an animal model of MS called experimental autoimmune encephalomyelitis (EAE) for the investigation, a common model used to study the pathogenesis of the disease. Mice whose Th17 cells cannot produce GM-CSF did not develop neuroinflammation, thus GM-CSF is responsible for disease manifestation in this experimental model. This scenario suggests feed-forward loop of IL-23 and GM-CSF driving the pathogenic encephalitogenic immune response in the brain and spinal cord.
Another recently published paper in Nature Immunology by Dr. Rostami and his team unraveled a mechanism that may help fight MS. The researchers found that a protein known as interkeukin-27 (IL-27) helped block, not induce, the onset of symptoms in animals with an MS-like disease. While increasing levels of GM-CSF may cause the disease, as shown in the current paper, increasing IL-27 concentrations may help quell an over-active immune system, the researchers reported.
"That was the first time that we had direct evidence that by actively giving IL-27 like a drug, we can suppress EAE in mice," Dr. Rostami said.
If similar findings from this current study of GM-CSF are found in human blood samples, this approach could eventually also be shown to be useful in the clinical setting, Dr. Rostami explains.
Whether GM-CSF drives neuroinflammation in MS remains unknown, but the current findings highlight the potential that IL-23 and GM-CSF might serve a similar role in human disease.
"This is the first step towards finding a new treatment," he said. "If we can try to neutralize GM-CSF by different means, for example, by trying to mimic it or trying to block the receptor for GM-CSF, we can hopefully ameliorate the disease."
Labels:
"Mary Jo Nickum",
"Mom's Story",
"MS Focus",
"multiple sclerosis",
MS,
treatment
Wednesday, April 20, 2011
Mother's Day
Consider giving a gift of love to Mother on Mother's Day: Mom’s Story, A Child Learns About MS.
Tuesday, April 19, 2011
Controlling the Muscle Spasms of Multiple Sclerosis
Many people with multiple sclerosis experience spasticity, or muscle stiffness and spasms. It usually affects the muscles of the legs and arms, and may interfere with the ability to move those muscles freely.
Spasticity can occur either as a sustained stiffness caused by increased muscle tone or as spasms that come and go, especially at night. It can feel like a muscle tightening or it can cause severe pain. Spasticity can also produce feelings of pain or tightness in and around joints and can cause low back pain. The intensity may vary depending on your position, posture, and state of relaxation.
What Causes Spasticity in Multiple Sclerosis?
Spasticity is the result of an imbalance in the electrical signals coming from the brain and spinal cord, often caused by damage to these areas from by multiple sclerosis. This imbalance causes hyperactive muscle stretch reflexes, which result in involuntary contractions of the muscle and increased muscle tension.
What Triggers Spasticity Due to Multiple Sclerosis?
For someone who has multiple sclerosis, spasticity may be aggravated by extremes of temperature, humidity, or infections. It can even be triggered by tight clothing.
How Is Spasticity Diagnosed?
To diagnose spasticity your doctor will first evaluate your medical history, including what medications you have taken and whether there is a history of neurological or muscular disorders in your family. To confirm the diagnosis, several tests can be performed to evaluate your arm and leg movements, muscular activity, passive and active range of motion, and ability to perform self-care activities.
How Is Spasticity Treated if I Have Multiple Sclerosis?
If you suffer from multiple sclerosis, spasticity can be treated using physical therapy, medications, surgery, or any combination of these treatments. Your doctors will consider the severity of your condition, your overall health, and the following factors when prescribing an appropriate treatment plan:
• Is the spasticity affecting function or independence?
• Is the spasticity painful?
• What treatment options have already been tried, and how did they work?
• What are the costs of the possible treatments?
• What are the limitations and side effects of the treatment?
• Will the benefits outweigh the risks?
How Does Physical and Occupational Therapy Help Spasticity?
A basic physical therapy stretching program is the first step in treating spasticity linked to MS. A daily regimen of stretching can lengthen muscles to help decrease spasticity.
An occupational therapist may prescribe splinting, casting, and bracing techniques to maintain range of motion and flexibility.
If physical and occupational therapy do not adequately control the spasticity, medications may be added to the treatment plan.
What Drugs Are Used to Treat Spasticity?
Common drugs used to treat spasticity include the muscle relaxants baclofen and Zanaflex.
Another drug that might be used to treat spasticity is Valium, which is often helpful when taken at night to relieve spasms that interfere with sleep.
If medications taken orally are not effective, a pump can be surgically implanted to deliver the medication (such as the baclofen pump). Botulinum toxin (or Botox) can also be injected locally into the affected area to relax the muscles.
What Types of Surgery Are Available for Spasticity?
When other treatments fail, rhizotomy and tendon release are two surgical procedures used to treat spasticity.
Rhizotomy involves surgically cutting away part of the spinal nerve. It is performed to relieve pain or decrease muscle tension.
Tendon release, also called a tenotomy, may be performed to help reduce the frequency or magnitude of the spasticity, depending on the age of the patient. The surgery involves cutting severely contracted tendons away from the muscles to which they're attached.
Tendon release may need to be repeated.
These surgeries are usually only done in extreme cases that do not respond to other treatments.
Friday, April 15, 2011
Study shoots hole in 'liberation' theory for multiple sclerosis
By Carmen Chai, Postmedia News
American researchers have cast fresh doubts on the theory underpinning so-called 'liberation therapy' for multiple sclerosis sufferers.
A new University of Buffalo study suggests that chronic cerebral venous insufficiency (CCSVI), which is a blocking or narrowing of extracranial veins that some researchers claim causes MS symptoms, may be a result of MS and not a cause.
"Given the intense interest in the hypothesis that CCSVI is a possible cause of MS, independent evaluation of CCSVI was identified an urgent need," said lead researcher Robert Zivadinov, a University of Buffalo neurology professor and president of the International Society for Neurovascular Disease.
Zivadinov's study, published Wednesday in the journal Neurology, examined 449 patients — 289 people who had MS, 163 who were healthy, 26 who had other neurological diseases and 21 who had experienced a clinically isolated syndrome (CIS), an individual's first neurological episode.
According to Zivadinov, results showed that only 56.1 per cent of MS patients and 38.1 per cent of CIS patients had CCSVI.
"While this may suggest an association between the MS and CCSVI, association does not imply causality," Zivadinov said in a statement.
Meanwhile, 42.3 per cent of participants who had other neurological diseases and 22.7 per cent of healthy people in the story also had CCSVI.
"These findings indicate that CCSVI does not have a primary role in causing MS. Our findings are consistent with increased prevalence of CCSVI in MS, but substantially lower than the sensitivity and specificity rates in MS reported originally by the Italian investigators," Zivadinov said in the press release.
Paolo Zamboni, a doctor at the University of Ferrara in Italy, had argued that CCSVI increased the risk of having MS by 43 times. The vascular condition restricts blood flow to the brain, which could cause muscle weakness and loss of sensitivity, he concluded.
Canadians suffering from MS have travelled abroad to Bulgaria, Poland, Mexico and other countries for the controversial liberation therapy procedure, which involves opening blocked veins in the neck. The procedure, developed by Zamboni, is banned in Canada because it is not scientifically supported.
Last November, a Niagara Falls, Ont., man died after he received liberation therapy at a hospital in Costa Rica.
Canada has one of the highest MS rates in the world.
cchai@postmedia.com
Read more: http://www.canada.com/health/Study+shoots+hole+liberation+theory+multiple+sclerosis/4611175/story.html#ixzz1JcZRduc0
Read more: http://www.canada.com/health/Study+shoots+hole+liberation+theory+multiple+sclerosis/4611175/story.html#ixzz1JcYXqzfu
American researchers have cast fresh doubts on the theory underpinning so-called 'liberation therapy' for multiple sclerosis sufferers.
A new University of Buffalo study suggests that chronic cerebral venous insufficiency (CCSVI), which is a blocking or narrowing of extracranial veins that some researchers claim causes MS symptoms, may be a result of MS and not a cause.
"Given the intense interest in the hypothesis that CCSVI is a possible cause of MS, independent evaluation of CCSVI was identified an urgent need," said lead researcher Robert Zivadinov, a University of Buffalo neurology professor and president of the International Society for Neurovascular Disease.
Zivadinov's study, published Wednesday in the journal Neurology, examined 449 patients — 289 people who had MS, 163 who were healthy, 26 who had other neurological diseases and 21 who had experienced a clinically isolated syndrome (CIS), an individual's first neurological episode.
According to Zivadinov, results showed that only 56.1 per cent of MS patients and 38.1 per cent of CIS patients had CCSVI.
"While this may suggest an association between the MS and CCSVI, association does not imply causality," Zivadinov said in a statement.
Meanwhile, 42.3 per cent of participants who had other neurological diseases and 22.7 per cent of healthy people in the story also had CCSVI.
"These findings indicate that CCSVI does not have a primary role in causing MS. Our findings are consistent with increased prevalence of CCSVI in MS, but substantially lower than the sensitivity and specificity rates in MS reported originally by the Italian investigators," Zivadinov said in the press release.
Paolo Zamboni, a doctor at the University of Ferrara in Italy, had argued that CCSVI increased the risk of having MS by 43 times. The vascular condition restricts blood flow to the brain, which could cause muscle weakness and loss of sensitivity, he concluded.
Canadians suffering from MS have travelled abroad to Bulgaria, Poland, Mexico and other countries for the controversial liberation therapy procedure, which involves opening blocked veins in the neck. The procedure, developed by Zamboni, is banned in Canada because it is not scientifically supported.
Last November, a Niagara Falls, Ont., man died after he received liberation therapy at a hospital in Costa Rica.
Canada has one of the highest MS rates in the world.
cchai@postmedia.com
Read more: http://www.canada.com/health/Study+shoots+hole+liberation+theory+multiple+sclerosis/4611175/story.html#ixzz1JcZRduc0
Read more: http://www.canada.com/health/Study+shoots+hole+liberation+theory+multiple+sclerosis/4611175/story.html#ixzz1JcYXqzfu
Labels:
"Carmen Chai",
"Liberation Therapy",
"multiple sclerosis",
Canada,
MS
Subscribe to:
Posts (Atom)